Abstract：
UNASSIGNED: Despite pharmacological treatments for osteoarthritis (OA), more individuals are choosing medical cannabis for OA symptom management and for mitigating opioid prescriptions for OA. This systematic review examines the global evidence of medical cannabis use on OA pain and function.
UNASSIGNED: The search was completed in MEDLINE (PubMed), Embase, and CINAHL within the past 10 years (2012-2022). We limited the search to English language articles. We did not include grey literature or case studies. Participant demographics included all adult individuals with OA who were using medical cannabis for OA. Study quality and risk of bias were evaluated using the Grading of Recommendations, Assessment, Development and Evaluations framework; and the Risk of Bias in Non-randomized Studies of Interventions tool. We used a narrative synthesis approach.
UNASSIGNED: Overall, 7 studies were included: 2 randomized controlled trials (RCT) and 5 observational studies. Only 1 of the 2 RCTs reported improvements in pain for cannabis users. All 5 observational studies reported an improvement in pain levels, reduction of opioid use, and/or improvement in overall OA function. Despite high risk of bias ratings and low study quality, the consensus across studies was that medical cannabis use was effective for a subgroup of individuals suffering from OA pain.
UNASSIGNED: There is low quality evidence to support medical cannabis use as a substitute for primary pharmacological treatment of OA. However, this does not negate the observations that medical cannabis may provide therapeutic relief for a subset of patients.
UNASSIGNED: CRD42022354026.
UNASSIGNED: The search was completed in MEDLINE (PubMed), Embase, and CINAHL within the past 10 years (2012-2022). We limited the search to English language articles. We did not include grey literature or case studies. Participant demographics included all adult individuals with OA who were using medical cannabis for OA. Study quality and risk of bias were evaluated using the Grading of Recommendations, Assessment, Development and Evaluations framework; and the Risk of Bias in Non-randomized Studies of Interventions tool. We used a narrative synthesis approach.
UNASSIGNED: Overall, 7 studies were included: 2 randomized controlled trials (RCT) and 5 observational studies. Only 1 of the 2 RCTs reported improvements in pain for cannabis users. All 5 observational studies reported an improvement in pain levels, reduction of opioid use, and/or improvement in overall OA function. Despite high risk of bias ratings and low study quality, the consensus across studies was that medical cannabis use was effective for a subgroup of individuals suffering from OA pain.
UNASSIGNED: There is low quality evidence to support medical cannabis use as a substitute for primary pharmacological treatment of OA. However, this does not negate the observations that medical cannabis may provide therapeutic relief for a subset of patients.
UNASSIGNED: CRD42022354026.
摘要：
■尽管对骨关节炎（OA）进行了药物治疗，越来越多的人选择医用大麻用于OA症状管理和减轻OA的阿片类药物处方.本系统综述审查了使用医用大麻治疗OA疼痛和功能的全球证据。
■搜索已在MEDLINE（PubMed）中完成，Embase,过去10年(2012-2022年)和CINAHL。我们只搜索英语文章。我们没有包括灰色文献或案例研究。参与者的人口统计数据包括所有使用医用大麻治疗OA的OA成年个体。研究质量和偏倚风险使用建议分级进行评估，评估,开发和评估框架；以及干预工具非随机研究中的偏倚风险。我们使用了叙事综合方法。
■总的来说，包括7项研究：2项随机对照试验（RCT）和5项观察性研究。2个RCT中只有1个报告了大麻使用者疼痛的改善。所有5项观察性研究都报告了疼痛水平的改善，减少阿片类药物的使用，和/或整体OA功能的改善。尽管偏倚评级风险高，研究质量低，各研究的共识是,医用大麻对患有OA疼痛的患者亚组有效.
■有低质量的证据支持使用医用大麻代替OA的主要药物治疗。然而,这并不能否定医用大麻可以为一部分患者提供治疗性缓解的观点。
■CRD42022354026。
■搜索已在MEDLINE（PubMed）中完成，Embase,过去10年(2012-2022年)和CINAHL。我们只搜索英语文章。我们没有包括灰色文献或案例研究。参与者的人口统计数据包括所有使用医用大麻治疗OA的OA成年个体。研究质量和偏倚风险使用建议分级进行评估，评估,开发和评估框架；以及干预工具非随机研究中的偏倚风险。我们使用了叙事综合方法。
■总的来说，包括7项研究：2项随机对照试验（RCT）和5项观察性研究。2个RCT中只有1个报告了大麻使用者疼痛的改善。所有5项观察性研究都报告了疼痛水平的改善，减少阿片类药物的使用，和/或整体OA功能的改善。尽管偏倚评级风险高，研究质量低，各研究的共识是,医用大麻对患有OA疼痛的患者亚组有效.
■有低质量的证据支持使用医用大麻代替OA的主要药物治疗。然而,这并不能否定医用大麻可以为一部分患者提供治疗性缓解的观点。
■CRD42022354026。
